Please login to the form below

Not currently logged in

Amarin slides as FDA panel votes against fish oil therapy

Advisory committee wants more data on Vascepa

amarin logoShares in Irish company Amarin Corp nosedived yesterday after a US Food and Drug Administration (FDA) advisory committee voted against approval of its fish oil-based therapy in a broader patient population.

By a 9-2 margin, the panel said it would not support approval of the omega-3 fatty acid based Vascepa (icosapent ethyl) as a combination therapy with statin drugs for people with elevated triglycerides (between 200 and 499mg/dL) until it is able to review data from an ongoing outcomes study called REDUCE-IT.

Amarin was hoping to win approval for Vascepa on the strength of data from the ANCHOR trial showing that taking the drug reduced elevated serum triglycerides, a risk factor for cardiovascular disease.

The negative votes seem to stem mainly from a wish to see hard endpoints and the view that while Vascepa's effects on triglycerides are clear, its effects on other lipids in the blood, such as low- and high-density lipoprotein-cholesterol (LDL-C and HDL-C) are less so.

Moreover, the FDA reviewer said in documents filed ahead of the meeting that recent trials in multiple drug classes "have failed to demonstrate a reduction in cardiovascular risk" when other lipid-altering treatment are added to statins.

One of the claims made by Amarin for Vascepa is that it reduces triglycerides without raising LDL-C, which could differentiate it from Lovaza/Omacor (omega-3-acid ethyl esters), another omega-fatty acid based product sold by GlaxoSmithKline (GSK), as well as other drug classes such as the fibrates.

The drug is already approved to reduce extremely high triglyceride levels (>500mg/dL) in patients not taking statins, but the broader indication is seen as key to its commercial success as such a high proportion of patients with dyslipidaemia take these drugs.

With the REDUCE-IT trial not due to generate results until 2017 (although an interim look at the data is due in 2015), the verdict could mean a lengthy delay for Vascepa and a major setback for the company's hope to grow its sales, which were a little over $7m in the first five months on the market since its US launch in January 2013.

Lovaza sales in the first half of this year were around $500m and ahead of the FDA committee meeting, analysts had suggested Vascepa could reach sales of $1bn or more as an adjunct to statin therapy.

Meanwhile, the cost of running REDUCE-IT is also a drain on Amarin's finances, with the bill for 2013 expected to come in at somewhere between $30m and $40m. The company was sitting on cash reserves of $150m at the end of June.

Article by
Phil Taylor

18th October 2013

From: Sales, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...